GSK PLC SP. ADR/2 NEW Total Assets
GSK PLC SP. ADR/2 NEW total assets. Based on the latest financial reports, GSK PLC SP. ADR/2 NEW (GS70) holds total assets worth €61.74 Billion EUR (≈ $72.18 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GSK PLC SP. ADR/2 NEW (GS70) total market value for the company's overall valuation and market capitalisation.
Total Assets of GSK PLC SP. ADR/2 NEW (2021–2025)
Total assets of GSK PLC SP. ADR/2 NEW from 2021 to 2025. This chart illustrates how GSK PLC SP. ADR/2 NEW's total assets have evolved over time, based on quarterly financial data. See GSK PLC SP. ADR/2 NEW stock price for real-time trading data and today's change.
GSK PLC SP. ADR/2 NEW - Asset Composition Analysis
GSK PLC SP. ADR/2 NEW Total Assets Breakdown (December 2025)
GSK PLC SP. ADR/2 NEW total assets breakdown as of December 2025. GSK PLC SP. ADR/2 NEW's total assets of €61.74 Billion consist of 28.7% current assets and 71.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.2% |
| Accounts Receivable | €5.91 Billion | 9.7% |
| Inventory | €5.92 Billion | 9.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €16.75 Billion | 27.4% |
| Goodwill | €7.02 Billion | 11.5% |
Asset Composition Trend (2021–2025)
This chart illustrates how GSK PLC SP. ADR/2 NEW's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore GS70 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GSK PLC SP. ADR/2 NEW's current assets represent 28.7% of total assets in 2025, an increase from 23.6% in 2021.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2025, the same as 5.2% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, a decrease from 51.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 27.4% of total assets.
GSK PLC SP. ADR/2 NEW Competitors by Total Assets
Key competitors of GSK PLC SP. ADR/2 NEW based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.18 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
GSK PLC SP. ADR/2 NEW - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 0.87 | 0.81 |
| Quick Ratio | 0.52 | 0.57 | 0.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-3.98 Billion | €-2.71 Billion | €-4.16 Billion |
GSK PLC SP. ADR/2 NEW - Advanced Valuation Insights
This section examines the relationship between GSK PLC SP. ADR/2 NEW's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.34 |
| Latest Market Cap to Assets Ratio | 1.66 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | €61.12 Billion |
| Market Capitalization | $101.34 Billion USD |
Valuation Analysis
Above Book Valuation: The market values GSK PLC SP. ADR/2 NEW's assets above their book value (1.66x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: GSK PLC SP. ADR/2 NEW's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GSK PLC SP. ADR/2 NEW (2021–2025)
The table below shows the annual total assets of GSK PLC SP. ADR/2 NEW from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €61.12 Billion ≈ $71.45 Billion |
+2.78% |
| 2024-12-31 | €59.46 Billion ≈ $69.52 Billion |
+0.78% |
| 2023-12-31 | €59.01 Billion ≈ $68.98 Billion |
-1.90% |
| 2022-12-31 | €60.15 Billion ≈ $70.32 Billion |
-23.96% |
| 2021-12-31 | €79.10 Billion ≈ $92.48 Billion |
-- |
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more